In this issue, Safa and Darrieux1 report a new and serious type of infection after rituximab therapy: cerebral toxoplasmosis. Although rituximab has helped many patients with lymphoma and autoimmune disease for more than 10 years, it has been linked to several major infectious complications.2 Reactivation of hepatitis B, cytomegalovirus disease, and the rare but fatal progressive multifocal leukoencephalopathy are the most infamous of these infections.
Linos E. Balancing the Risks and Benefits of Rituximab. JAMA Intern Med. 2013;173(10):920–937. doi:10.1001/jamainternmed.2013.743
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: